Novo Nordisk reports EPS for the first three months of 2024 up 29% to DKK 5.68, and operating profit up 27% (+30% at constant exchange rates) to over DKK 31.8 billion.

The Danish pharmaceutical company, which specializes in the treatment of diabetes and obesity, saw sales rise by 22% (+24% at CER) to over 65.3 billion, supported in particular by the US market.

For 2024 as a whole, at TCC, sales growth is now expected to be between 19% and 27%, and operating profit between 22% and 30%, target ranges up one point on previous ones.

Copyright (c) 2024 CercleFinance.com. All rights reserved.